Abstract This study analyzed the clinical features of 5 children with hereditary spherocytosis (HS) and the characteristics of ANK1 and SPTB gene mutations. All 5 children were confirmed with HS by peripheral blood genetic detection. Anemia, jaundice and splenomegaly were observed in all 5 children. Three children had an increase in erythrocyte osmotic fragility. All 5 children had negative results of the Coombs test, glucose 6 phosphate dehydrogenase test, sucrose hemolysis test, acidified-serum hemolysis test and thalassemia gene test. Peripheral blood smear showed an increase in spherocyte count in one child. High-throughput sequencing revealed ANK1 gene mutations in patients 1 to 3, namely c.3398(exon29)delA, c.4306C > T and c.957(exon9)_c.961(exon9)delAATCT, among which c.3398(exon29)delA had not been reported before. Patient 4 had c.318delGExon3 mutation in the SPTB gene. Patient 5 had mutations in the SPTB and SLC4A1 genes, among which c.3484delC in the SPTB gene was a spontaneous mutation; the mutation site of the SLCA4A1 gene was inherited from the father and was a non-pathogenic gene. This study suggests that anemia, jaundice and splenomegaly are major clinical manifestations of HS children. Most children with HS do not have the typical spherocytic changes. Genetic detection may help with the accurate diagnosis of HS.
GONG Jun,HE Xiang-Ling,ZOU Run-Ying et al. Clinical characteristics and genetic analysis of hereditary spherocytosis caused by mutations of ANK1 and SPTB genes[J]. CJCP, 2019, 21(4): 370-374.
GONG Jun,HE Xiang-Ling,ZOU Run-Ying et al. Clinical characteristics and genetic analysis of hereditary spherocytosis caused by mutations of ANK1 and SPTB genes[J]. CJCP, 2019, 21(4): 370-374.
Ma S, Deng X, Liao L, et al. Analysis of the causes of the misdiagnosis of hereditary spherocytosis[J]. Oncol Rep, 2018, 40(3):1451-1458.
[7]
Deng Z, Liao L, Yang W, et al. Misdiagnosis of two cases of hereditary spherocytosis in a family and review of published reports[J]. Clin Chim Acta, 2015, 441:6-9.
[8]
Gallagher PG. Abnormalities of the erythrocyte membrane[J]. Pediatr Clin North Am, 2013, 60(6):1349-1362.
Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary spherocytosis:a comparison study in 150 patients grouped according to molecular and clinical characteristics[J]. Haematologica, 2012, 97(4):516-523.
[13]
Hunt L, Greenwood D, Heimpel H, et al. Toward the harmonization of result presentation for the eosin-5'-maleimide binding test in the diagnosis of hereditary spherocytosis[J]. Cytometry B Clin Cytom, 2015, 88(1):50-57.
[14]
Arora RD, Dass J, Maydeo S, et al. Flow cytometric osmotic fragility test and eosin-5'-maleimide dye-binding tests are better than conventional osmotic fragility tests for the diagnosis of hereditary spherocytosis[J]. Int J Lab Hematol, 2018, 40(3):335-342.
[15]
Ma S, Deng X, Liao L, et al. Analysis of the causes of the misdiagnosis of hereditary spherocytosis[J]. Oncol Rep, 2018, 40(3):1451-1458.
[16]
Chari PS, Prasad S. Flow cytometric eosin-5'-maleimide test is a sensitive screen for hereditary spherocytosis[J]. Indian J Hematol Blood Transfus, 2018, 34(3):491-494.
[17]
Crisp RL, Solari L, Vota D, et al. A prospective study to assess the predictive value for hereditary spherocytosis using five laboratory tests (cryohemolysis test, eosin-5'-maleimide flow cytometry, osmotic fragility test, autohemolysis test, and SDSPAGE) on 50 hereditary spherocytosis families in Argentina[J]. Ann Hematol, 2011, 90(6):625-634.
[18]
Russo R, Andolfo I, Manna F, et al. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias[J]. Am J Hemato, 2018, 93(5):672-682.
[19]
Wang X, Yi B, Mu K, et al. Identification of a novel de novo ANK1 R1426* nonsense mutation in a Chinese family with hereditary spherocytosis by NGS[J]. Oncotarget, 2017, 8(57):96791-96797.
[20]
Chen J, Zhou Y, Gao Y, et al. A genetic features and gene interaction study for identifying the genes that cause hereditary spherocytosis[J]. Hematology, 2017, 22(4):240-247.
[21]
Narla J, Mohandas N. Red cell membrane disorders[J]. Int J Lab Hematol, 2017, 39(Suppl 1):47-52.
[22]
Delaunay J. The molecular basis of hereditary red cell membrane disorders[J]. Blood Rev, 2007, 21(1):1-20.
[23]
He BJ, Liao L, Deng ZF, et al. Molecular genetic mechanisms of hereditary spherocytosis:current perspectives[J]. Acta Haematol, 2018, 139(1):60-66.
[24]
Wang R, Yang S, Xu M, et al. Exome sequencing confirms molecular diagnoses in 38 Chinese families with hereditary spherocytosis[J]. Sci China Life Sci, 2018, 61(8):947-953.
[25]
Luo Y, Li Z, Huang L, et al. Spectrum of ankyrin mutations in hereditary spherocytosis:a case report and review of the literature[J]. Acta Haematol, 2018, 140(2):77-86.
[26]
Miraglia del Giudice E, Francese M, Nobili B, et al. High frequency of de novo mutations in ankyrin gene (ANK1) in children with hereditary spherocytosis[J]. J Pediatr, 1998, 132(1):117-120.
Park J, Jeong DC, Yoo J, et al. Mutational characteristics of ANK1 and SPTB genes in hereditary spherocytosis[J]. Clin Genet, 2016, 90(1):69-78.
[29]
Chong J, Jones P, Spelman D, et al. Overwhelming postsplenectomy sepsis in patients with asplenia and hyposplenia:a retrospective cohort study[J]. Epidemiol Infect, 2017, 145(2):397-400.
[30]
Kimmig LM, Palevsky HI. Review of the association between splenectomy and chronic thromboembolic pulmonary hypertension[J]. Ann Am Thorac Soc, 2016, 13(6):945-954.
[31]
Pugi J, Carcao M, Drury LJ, et al. Results after laparoscopic partial splenectomy for children with hereditary spherocytosis:are outcomes influenced by genetic mutation?[J]. J Pediatr Surg, 2018, 53(5):973-975.
